YBIOLOGICS possesses a top-tier antibody discovery platform and a proprietary T-cell bispecific antibody platform. Its core technologies include the Ymax®-ABL, a fully human antibody library for antibody discovery, and the ALiCE platform, an innovative T-cell engaging bispecific antibody format for immuno-oncology therapies. The company's main business activities include licensing out internally developed antibody drugs, securing equity in jointly developed antibody drugs, and providing contract research services.

The Ymax-ABL is a fully human antibody (naïve cDNA) library that boasts over 120 billion gene variations, meaning Y-Biologics possesses more than 120 billion distinct antibody genes. This platform is derived from the cDNA of human immune cells (B cells), resulting in lower immunogenicity compared to synthetic libraries. Immunogenicity refers to the strength of an antigen in triggering an immune response. Additionally, Ymax-ABL offers excellent antibody productivity and physical properties. Through its next-generation T-cell bispecific antibody platform, ALiCE, Y-Biologics is developing the immuno-oncology candidate YBL-013, which was licensed to 3D Medicines for exclusive rights in China before entering preclinical trials. The ALiCE platform enhances anticancer effects by binding to both cancer cells and T cells while limiting toxicity. The technology has been granted a patent in the United States.

Public

Biotech, R&D Service